The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1447077
Effects of fermented Arctium lappa L. root by Lactobacillus casei on hyperlipidemic mice
Provisionally accepted- 1 Guangdong Pharmaceutical University, Guangzhou, China
- 2 Shenzhen Baoan People's Hospital, Shenzhen, Guangdong Province, China
- 3 Hunan University of Medicine, Huaihua, Hunan Province, China
This study aimed to establish a fermentation system based on Lactobacillus casei (LC) and Arctium lappa L. root (AR), elucidate differences in metabolites' pre-and post-fermentation using untargeted metabolomics, and assess the impact of LC-AR on gut microbiota in high fat diet-induced hyperlipidemic mice. Compared to AR, LC-AR exhibited stronger in vitro antioxidant activity and higher levels of metabolites. Moreover, it demonstrated improved liver injury as well as better regulation of lipid levels, pro-inflammatory cytokine levels, and cholesterol-related mRNA. According to the 16S rRNA analysis, LC-AR reduced the relative abundance of Firmicutes/Bacteroidetes at the phylum level, which was significantly negatively correlated with triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels. Thus, LC-AR has promising potential as functional food and drug raw materials in improving hyperlipidemia.Hyperlipidemia is a metabolic illness characterized by excessive lipid levels and is a key risk factor for stroke and cardiovascular diseases (Crea et al., 2023;Alloubani et al., 2021;Stewart et al., 2020) Multiple clinical studies have proved that statins and fibrates exhibit good performance in
Keywords: Arctium lappa L. root, Lactobacillus, Fermented, Hyperlipidemia, Lipid level, Gut Microbiota
Received: 11 Jun 2024; Accepted: 09 Oct 2024.
Copyright: © 2024 Chen, Wu, Yang, Liu, Han, Dai, Chen, Ouyang, Chen, Liu, Zhou and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jian-xin Liu, Hunan University of Medicine, Huaihua, 418000, Hunan Province, China
Lin Zhou, Guangdong Pharmaceutical University, Guangzhou, China
XuGuang Hu, Guangdong Pharmaceutical University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.